Jason M. Broderick is a journalist at various esteemed publications, including Diagnostic Imaging®, Cancer Network, and CURE Media Group. He focuses on themes related to medicine and healthcare, particularly in oncology, pancreatic cancer research, immunotherapy, and palliative care. His work has been featured in prominent outlets such as Urology Times, AJMC - The American Journal of Managed Care, and Oncology Nursing News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Jason M. Broderick's coverage predominantly revolves around healthcare and pharmaceutical topics, with a particular focus on scientific research and data-driven insights in the medical field. His articles often cite specific data, indicating an emphasis on evidence-based reporting.
Given his engagement with scientific findings and healthcare advancements, he is likely to be interested in pitches that offer access to new clinical studies, innovative medical technologies, or expert commentary from professionals involved in cutting-edge research within the specified medical domains. Pitches centered around breakthroughs related to bladder cancer treatment modalities, biomarker discoveries, urine testing innovations, or cancer diagnosis methodologies could align well with his coverage interests.
As Jason’s geographic focus is not specified but the content of his articles indicates a broad international perspective focused on developments across various regions without restriction to any specific location.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Jonah Feldman, Jason M. Broderick
FDA breakthrough device designation was supported by MERLIN_001, positioning Merlin CP-GEP for expedited regulatory interaction as a diagnostic adjunct in early-stage melanoma management decisions. NCCN endorses selective CP-GEP use for SLNB decision-making in T1b/T2a melanoma when clinicians would forgo SLNB below a 10% nodal-risk threshold.
By: Jason M. Broderick
Combining zoldonrasib with mFOLFIRINOX yielded ORR 82% and DCR 96%, with grade ≥3 TRAEs in 61% and predominant hematologic toxicity typical of the backbone. Pairing zoldonrasib with gemcitabine/nab-paclitaxel delivered ORR 61% and DCR 90%, with grade ≥3 TRAEs in 80% and no grade 5 treatment-related events.
By: Jason M. Broderick
The next-generation KRAS G12C inhibitor improved survival vs the approved first-generation agents sotorasib and adagrasib.
By: Sabrina Serani, Jason M. Broderick
Enrollment randomized 240 patients to radiotherapy (50.4 Gy/28 fractions) and 238 to dose-dense temozolomide, yielding OS 6.6 vs 8.0 years and PFS 3.6 vs 3.1 years. 2021 WHO reclassification (73% with tissue) showed IDH-mutant noncodeleted astrocytoma OS ~6.6–6.7 years and IDH-mutant 1p/19q-codeleted oligodendroglioma OS ~12.9–14.9 years, irrespective of arm.
By: Jason M. Broderick
Building on these data, the ongoing phase 3 BATTMAN trial is exploring botensilimab plus balstilimab in refractory MSS mCRC.
By: Jason M. Broderick, Sabrina Serani
Dual-primary end points were negative: BICR PFS 7.5 vs 8.1 months (HR 0.89; P=.32) and OS 21.6 vs 21.7 months (HR 0.83; P=.09) for adagrasib/cetuximab versus chemotherapy.
By: Jason M. Broderick
During a live event, Kristen M. Pettit, MD, and participants discussed second-line considerations in high-risk polycythemia after hydroxyurea failure.
By: Jason M. Broderick
FDA cleared pegfilgrastim-pccg for the same indications as pegfilgrastim, including chemotherapy-associated febrile neutropenia prophylaxis and survival benefit after myelosuppressive radiation exposure causing Hematopoietic Subsyndrome of ARS.
By: Jason M. Broderick
KEYNOTE-C93 demonstrated BICR-assessed PFS superiority for pembrolizumab monotherapy over platinum doublet chemotherapy in frontline dMMR advanced/recurrent endometrial cancer. Overall survival trended positively with pembrolizumab, but immature data preclude definitive conclusions regarding survival advantage vs chemotherapy.
By: Jason M. Broderick
INVINCIBLE-4 randomizes operable TNBC to INT230-6 pre-treatment followed by KEYNOTE-522–like neoadjuvant pembrolizumab/chemotherapy versus standard therapy alone, with pCR in breast and nodes as primary endpoint. Accrual restarted after protocol amendments addressing cutaneous irritation by reducing drug-to-tumor volume ratio and switching to a single intratumoral injection, with enrollment planned across Switzerland and France.
